One investor wants protection in Myriad Genetics, which
reports earnings in two weeks.
optionMONSTER's Depth Charge monitoring system detected the
purchase of 1,000 September 23 puts for $0.64 and sale of an equal
number of September 28 calls for $0.64. There was barely any open
interest in either strike before the trade appeared.
The position cost essentially nothing to open and is leveraged to
downside in the drug maker. It will make money on a drop below $23
and force the investor to sell shares above $28--a level it hasn't
seen in almost three years.
MYGN is down 1.24 percent to $25.58 in morning trading but is up 22
percent so far this year. Earnings and revenue beat expectations
the last results came out on May 1, when management also raised
guidance. The previous release in January was strong as well.
With the next report scheduled for after the bell on Aug. 14,
today's trader is apparently looking for a hedge. He or she
probably owns stock and would be willing to unload on a rally to
$28. The main thing they seem to want is downside protection in the
event of a drop. (See our
section for more on the strategy, known as a
The trade pushed total option volume in the name to 11 times
greater than average.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.